Drug development is highly warranted in genomic alterations of the PI3K (PTEN and PIK3CA), RAS (KRAS), and wnt/β-catenin (CTNNB1) pathways in endometrioid carcinomas and TP53, ERBB2, and PIK3CA in non-endometrioid carcinomas (Table 1). Here, PIK3CA is linked to endometrioid adenocarcinoma.